Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort
| Autor: | Maria Letizia Urban, Enrico Brunetta, Giuseppe A. Ramirez, Francesco Benvenuti, Giacomo Emmi, Giulia Pazzola, Michela Gasparotto, Elena Bartoloni, Mariele Gatto, Elisa Gremese, Micaela Fredi, Maria Gerosa, Paolo Cardinaletti, Francesco Ciccia, Giovanni Orsolini, Marta Mosca, Amato de Paulis, Luca Iaccarino, Paola Faggioli, Enrica Bozzolo, Tania Ubiali, Fulvia Ceccarelli, Alessandra Bortoluzzi, Fabrizio Conti, Antonella Laria, Serena Fasano, Chiara Tani, Salvatore Scarpato, Angela Tincani, Marcello Govoni, Laura Andreoli, Carlo Salvarani, Roberto Gerli, Francesca Regola, Maddalena Larosa, Francesca Wanda Rossi, Armando Gabrielli, Ginevra De Marchi, Margherita Zen, Luca Petricca, Francesca Saccon, Maurizio Rossini, Valentina Canti, Salvatore De Vita, Andrea Doria |
|---|---|
| Přispěvatelé: | Gatto, M., Saccon, F., Andreoli, L., Bartoloni, E., Benvenuti, F., Bortoluzzi, A., Bozzolo, E., Brunetta, E., Canti, V., Cardinaletti, P., Ceccarelli, F., Ciccia, F., Conti, F., De Marchi, G., de Paulis, A., De Vita, S., Emmi, G., Faggioli, P., Fasano, S., Fredi, M., Gabrielli, A., Gasparotto, M., Gerli, R., Gerosa, M., Govoni, M., Gremese, E., Laria, A., Larosa, M., Mosca, M., Orsolini, G., Pazzola, G., Petricca, L., Ramirez, G. A., Regola, F., Rossi, F. W., Rossini, M., Salvarani, C., Scarpato, S., Tani, C., Tincani, A., Ubiali, T., Urban, M. L., Zen, M., Doria, A., Iaccarino, L. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Settore MED/16 - REUMATOLOGIA Lupus nephritis Kidney Gastroenterology Renal response Cohort Studies chemistry.chemical_compound Immunosuppressive Agent Monoclonal B-Cell Activating Factor Immunology and Allergy Lupus Erythematosus Systemic Humanized Proteinuria Systemic lupus erythematosus Standard treatment Middle Aged Lupus Nephritis Treatment Outcome Italy Cohort Belimumab Adult Antibodies Monoclonal Humanized Female Follow-Up Studies Glomerular Filtration Rate Humans Immunosuppressive Agents medicine.symptom medicine.drug Human medicine.medical_specialty Immunology Renal function Antibodies NO Follow-Up Studie Internal medicine medicine Creatinine Lupus Erythematosus business.industry Lupus nephriti Systemic medicine.disease chemistry Cohort Studie business |
| Popis: | Background: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN). Aim: To evaluate renal response and its predictors in LN patients receiving belimumab in real-life. Patients and methods: We considered all patients fulfilling the SLEDAI-2K renal items and/or having estimated glomerular filtration rate (eGFR)≤60 ml/min/1.73 m2, with positive anti-dsDNA and/or low C3/C4 enrolled in the multicentre Italian lupus cohort BeRLiSS (BElimumab in Real LIfe Setting Study), treated with monthly IV Belimumab 10 mg/kg over standard treatment. Primary efficacy renal response (PERR), defined as proteinuria ≤0.7 g/24 h, eGFR≥60 ml/min/1.73 m2 without rescue therapy, was considered as primary outcome. Complete renal response (CRR; proteinuria |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|